Parvis Sadjadian

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations Pretreated With Reversible EGFR Inhibitors

David F. Heigener, Christian Schumann, Martin Sebastian et al. · The Oncologist · 2015 · 87 citations · Full text

Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

Frank Griesinger, Wilfried Eberhardt, Arnd Nusch et al. · Lung Cancer · 2020 · 83 citations · Full text

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Michael Thomas, Santiago Ponce-Aix, Alejandro Navarro et al. · Annals of Oncology · 2018 · 80 citations · Full text

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Parvis Sadjadian, Jens Kollmeier et al. · Investigational New Drugs · 2017 · 50 citations · Full text